BBNX insider transaction filings
Beta Bionics, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-18. Screen BBNX transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 15 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 17 legs across 15 filings by 6 insiders — 172,838 shares, $3,245,317 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 8.
- Largest priced transaction: sale of 36,870 shares @ $18.46 ($680,723) by Hopman Mark, filed 2026-09-10.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Hopman Mark — Chief Commercial Officer | 6 | — | 6 legs · 111,003 sh · $2,097,637 | — |
| Feider Stephen — Chief Financial Officer | 3 | — | 5 legs · 26,675 sh · $468,354 | 8 |
| Saint Sean — President & CEO, Director | 2 | — | 2 legs · 22,508 sh · $435,640 | — |
| Mensinger Mike — Chief Product Officer | 2 | — | 2 legs · 7,025 sh · $141,920 | — |
| Russell Steven Jon — Chief Medical Officer | 1 | — | 1 leg · 4,221 sh · $80,676 | — |
| Jones Christy — Director | 1 | — | 1 leg · 1,406 sh · $21,090 | — |
Recent Form 4 filings — Beta Bionics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-18 | 4/A | Hopman Mark — Chief Commercial Officer | Sale (S): 35,994 @ $18.46 | EDGAR |
| 2026-09-17 | 4 | Mensinger Mike — Chief Product Officer | Sale (S): 2,650 @ $22 | EDGAR |
| 2026-09-17 | 4 | Hopman Mark — Chief Commercial Officer | Sale (S): 30,779 @ $20.13 | EDGAR |
| 2026-09-15 | 4 | Hopman Mark — Chief Commercial Officer | Sale (S): 775 @ $15.52 | EDGAR |
| 2026-09-10 | 4 | Hopman Mark — Chief Commercial Officer | Sale (S): 36,870 @ $18.46 | EDGAR |
| 2026-09-04 | 4 | Saint Sean — President & CEO, Director | Sale (S): 5,641 @ $20.08 | EDGAR |
| 2026-09-03 | 4 | Saint Sean — President & CEO, Director | Sale (S): 16,867 @ $19.11 | EDGAR |
| 2026-09-03 | 4 | Feider Stephen — Chief Financial Officer | Sale (S): 6,675 @ $19.11 | EDGAR |
| 2026-09-03 | 4 | Mensinger Mike — Chief Product Officer | Sale (S): 4,375 @ $19.11 | EDGAR |
| 2026-09-03 | 4 | Russell Steven Jon — Chief Medical Officer | Sale (S): 4,221 @ $19.11 | EDGAR |
| 2026-09-03 | 4 | Hopman Mark — Chief Commercial Officer | Sale (S): 5,327 @ $19.11 | EDGAR |
| 2026-07-02 | 4/A | Feider Stephen — Chief Financial Officer | Option exercise (M): 5,104 @ $5.10 · Sale (S): 5,104 @ $17.05 · Option exercise (M): 4,896 @ $5.10 · Sale (S): 4,896 @ $17.03 · Option exercise (M): 5,104 (derivative) @ $0 · Option exercise (M): 4,896 (derivative) @ $0 | EDGAR |
| 2026-06-30 | 4 | Feider Stephen — Chief Financial Officer | Option exercise (M): 4,982 @ $5.10 · Sale (S): 5,104 @ $17.05 · Option exercise (M): 4,896 @ $5.10 · Sale (S): 4,896 @ $17.03 · Option exercise (M): 4,982 (derivative) @ $0 · Option exercise (M): 4,896 (derivative) @ $0 | EDGAR |
| 2026-06-25 | 4 | Hopman Mark — Chief Commercial Officer | Sale (S): 1,258 @ $15.01 | EDGAR |
| 2026-06-25 | 4 | Jones Christy — Director | Sale (S): 1,406 @ $15 | EDGAR |
| 2026-06-05 | 4 | Hopman Mark — Chief Commercial Officer | Sale (S): 275 @ $12.31 | EDGAR |
| 2026-06-05 | 4 | Jones Christy — Director | Sale (S): 2,811 @ $14 | EDGAR |
| 2026-06-03 | 4 | Russell Steven Jon — Chief Medical Officer | Sale (S): 4,222 @ $12.61 | EDGAR |
| 2026-06-03 | 4 | Saint Sean — President & CEO, Director | Sale (S): 16,872 @ $12.61 | EDGAR |
| 2026-06-03 | 4 | Feider Stephen — Chief Financial Officer | Sale (S): 6,676 @ $12.61 | EDGAR |
| 2026-06-03 | 4 | Mensinger Mike — Chief Product Officer | Sale (S): 4,378 @ $12.61 | EDGAR |
| 2026-06-03 | 4 | Hopman Mark — Chief Commercial Officer | Sale (S): 5,329 @ $12.61 | EDGAR |
| 2026-05-26 | 4 | Jones Christy — Director | Sale (S): 1,998 @ $9.95 · Grant/award (A): 16,965 @ $0 | EDGAR |
| 2026-05-26 | 4 | Lezack Adam — Director | Sale (S): 1,000 @ $9.95 · Grant/award (A): 16,965 @ $0 · Sale (S): 998 @ $11.21 | EDGAR |
| 2026-05-26 | 4 | Palasis Maria — Director | Grant/award (A): 16,965 @ $0 | EDGAR |
| 2026-05-26 | 4 | Dearen Danny L. — Director | Grant/award (A): 16,965 @ $0 | EDGAR |
| 2026-05-26 | 4 | CARNEY SEAN — Director | Grant/award (A): 16,965 @ $0 | EDGAR |
| 2026-05-26 | 4 | MICHEL GERARD J — Director | Grant/award (A): 16,965 @ $0 | EDGAR |
| 2026-03-16 | 4 | Russell Steven Jon — Chief Medical Officer | Sale (S): 1,025 @ $29.34 | EDGAR |
| 2026-03-16 | 4 | Hopman Mark — Chief Commercial Officer | Sale (S): 856 @ $29.34 · Sale (S): 2,061 @ $30.66 | EDGAR |
| 2026-03-13 | 4/A | Russell Steven Jon — Chief Medical Officer | Grant/award (A): 91,520 (derivative) @ $0 | EDGAR |
| 2026-03-13 | 4/A | Saint Sean — President & CEO, Director | Grant/award (A): 287,944 (derivative) @ $0 | EDGAR |
| 2026-03-13 | 4/A | Feider Stephen — Chief Financial Officer | Grant/award (A): 110,342 (derivative) @ $0 | EDGAR |
| 2026-03-13 | 4/A | Mensinger Mike — Chief Product Officer | Grant/award (A): 91,520 (derivative) @ $0 | EDGAR |
| 2026-03-13 | 4/A | Hopman Mark — Chief Commercial Officer | Grant/award (A): 91,520 (derivative) @ $0 | EDGAR |
| 2026-03-05 | 4 | Hopman Mark — Chief Commercial Officer | Sale (S): 353 @ $11.57 | EDGAR |
| 2026-03-03 | 4 | Russell Steven Jon — Chief Medical Officer | Grant/award (A): 109,105 @ $0 · Sale (S): 1,026 @ $12.36 · Grant/award (A): 58,749 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Saint Sean — President & CEO, Director | Grant/award (A): 343,269 @ $0 · Sale (S): 3,384 @ $12.36 · Grant/award (A): 184,837 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Feider Stephen — Chief Financial Officer | Grant/award (A): 131,543 @ $0 · Sale (S): 1,428 @ $12.36 · Grant/award (A): 70,831 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Mensinger Mike — Chief Product Officer | Grant/award (A): 109,105 @ $0 · Sale (S): 1,064 @ $12.36 · Grant/award (A): 58,749 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Hopman Mark — Chief Commercial Officer | Grant/award (A): 109,105 @ $0 · Sale (S): 834 @ $12.36 · Grant/award (A): 58,749 (derivative) @ $0 | EDGAR |
| 2026-01-14 | 4 | Jones Christy — Director | Grant/award (A): 3,997 @ $0 | EDGAR |
| 2026-01-14 | 4 | Lezack Adam — Director | Grant/award (A): 3,997 @ $0 | EDGAR |
| 2026-01-14 | 4 | Palasis Maria — Director | Grant/award (A): 3,997 @ $0 | EDGAR |
| 2026-01-14 | 4 | Dearen Danny L. — Director | Grant/award (A): 3,997 @ $0 | EDGAR |
| 2026-01-14 | 4 | CARNEY SEAN — Director | Grant/award (A): 3,997 @ $0 | EDGAR |
| 2026-01-14 | 4 | MICHEL GERARD J — Director | Grant/award (A): 3,997 @ $0 | EDGAR |
| 2026-01-07 | 4 | Mensinger Mike — Chief Product Officer | Sale (S): 2,200 @ $30.10 | EDGAR |
| 2026-01-05 | 4 | Feider Stephen — Chief Financial Officer | Option exercise (M): 20,000 @ $5.10 · Sale (S): 20,000 @ $29.53 · Option exercise (M): 20,000 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Mensinger Mike — Chief Product Officer | Sale (S): 7,200 @ $29.56 · Sale (S): 600 @ $30.20 | EDGAR |
Recent 8-K events — Beta Bionics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-17 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-15 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-29 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-22 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-21 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-21 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-17 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-30 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-01-08 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-10-28 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=BBNX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →